NCT06927999View on ClinicalTrials.gov

An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria

PHASE2RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

July 9, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Urticaria Chronic
Interventions
DRUG

Placebo

Placebo solution nasal spray containing no active drug

DRUG

0.5 mg epinephrine

0.5 mg epinephrine per spray

DRUG

1 mg epinephrine

1 mg epinephrine per spray

Trial Locations (3)

45236

RECRUITING

Bernstein Clinical Research Center, LLC, Cincinnati

60026

RECRUITING

Endeavor Health Clinical Trials Center, Glenview

Unknown

NOT_YET_RECRUITING

"Institute of Allergology IFA Charité - Campus Benjamin Franklin , Hindenburgdamm 30"

Sponsors
All Listed Sponsors
lead

ARS Pharmaceuticals, Inc.

INDUSTRY